Mohr John, Johnson Melissa, Cooper Travis, Lewis James S, Ostrosky-Zeichner Luis
Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Pharmacotherapy. 2008 May;28(5):614-45. doi: 10.1592/phco.28.5.614.
Infections caused by yeasts and molds continue to be associated with high rates of morbidity and mortality in both immunocompromised and immunocompetent patients. Many antifungal drugs have been developed over the past 15 years to aid in the management of these infections. However, treatment is still not optimal, as the epidemiology of the fungal infections continues to change and the available antifungal agents have varying toxicities and drug-interaction potential. Several investigational antifungal drugs, as well as nonantifungal drugs, show promise for the management of these infections.
酵母菌和霉菌引起的感染在免疫功能低下和免疫功能正常的患者中仍然与高发病率和死亡率相关。在过去15年里，已经研发出许多抗真菌药物来帮助治疗这些感染。然而，由于真菌感染的流行病学不断变化，且现有的抗真菌药物具有不同的毒性和药物相互作用潜力，治疗仍不理想。几种研究性抗真菌药物以及非抗真菌药物在治疗这些感染方面显示出前景。
